Last updated: February 13, 2026
What is the drug associated with NDC 52427-0775?
NDC 52427-0775 corresponds to Xyosted** (testosterone enanthate) 250 mg/mL injection. It is a testosterone replacement therapy approved for adult males with hypogonadism caused by medical conditions.
What is the current market landscape?
Market size and demand
- The global testosterone replacement therapy (TRT) market was valued at approximately USD 2.3 billion in 2022.
- The U.S. accounts for over 70% of the global market share.
- The U.S. TRT patient population is estimated at 4 million males aged 40-65.
- Annual prescriptions for testosterone products in the U.S. exceed 15 million.
- Demand is driven by increased awareness and aging male populations.
Competitive landscape
- Major products include gel formulations (AndroGel), topical patches (AndroDerm), injections (Depo-Testosterone, Aveed), and implants.
- Xyosted entered the market around 2019, offering a subcutaneous injection, with existing competitors primarily offering intramuscular injections or topical formulations.
- Market share among injectable testosterone products remains around 40%, with Xyosted capturing approximately 15-20% of the injectable segment.
Regulatory environment
- The FDA approved Xyosted in 2018, with initial commercialization in 2019.
- Labeling restricts use to adult males with documented hypogonadism.
- Prescribing practices are influenced by guidelines from the Endocrine Society and other medical bodies.
- Increasing scrutiny due to potential cardiovascular and prostate risks.
What factors influence pricing and projections?
Pricing dynamics
- The average wholesale price (AWP) for Xyosted is approximately USD 1,200 per 10 mL vial (250 mg/mL concentration).
- The average patient treatment duration per vial is 2-4 weeks, depending on dosage.
- Insurance coverage affects out-of-pocket costs; co-pays can range from USD 50-200 per month.
Pricing trends
- Brand-name injectable testosterone products typically range from USD 1,000 to USD 2,500 per vial.
- Biosimilars are not yet present in this segment, maintaining higher prices for branded products.
- Formulation innovations or new entrants could influence pricing downward.
Market growth projections
- The TRT market is expected to grow at CAGRs of 4-6% through 2030.
- Increased diagnosis and acceptance of testosterone therapy support incremental growth.
- Potential market constraints include FDA regulatory actions, safety concerns, and alternative treatment modalities.
What are the future price projections?
| Year |
Estimated Average Wholesale Price (USD) per vial |
Notes |
| 2023 |
1,200 |
Current price point |
| 2025 |
1,150–1,250 |
Marginal decrease due to competitive pressure |
| 2030 |
1,000–1,200 |
Possible entry of biosimilars or formulation shifts |
- Pricing pressures are expected to keep the average price per vial stable or slightly declining as competitors attempt to capture market share.
- Future value may also be affected by increased biosimilar development, although none currently exist for testosterone enanthate.
Implications for stakeholders
- Pharmaceutical companies should monitor competitive dynamics and regulatory changes affecting pricing.
- Investors might consider the stability of the TRT market, bearing in mind safety concerns and reimbursement patterns.
- Practitioners should stay abreast of evolving guidelines and formulary restrictions that could impact prescribing behaviors.
Key Takeaways
- NDC 52427-0775 corresponds to Xyosted, a subcutaneous testosterone injection.
- The market is mature, with established competitors and steady demand.
- Current prices range from USD 1,200 per vial, with slight downward pressure likely over the next five years.
- Market growth remains steady, supported by demographic trends but influenced by safety concerns and regulatory oversight.
- Future price trends suggest potential stabilization or minor declines, especially with emerging biosimilar options.
FAQs
1. How does Xyosted compare with other testosterone therapies in cost?
Xyosted's price per vial is comparable to other injectable forms but tends to be higher than topical options. Costs depend on formulation, dosage, and insurance coverage.
2. Are biosimilars likely to emerge for testosterone enanthate?
Currently, no biosimilars are approved. However, regulatory pathways are evolving, and biosimilars could enter the market within the next 5-7 years.
3. What factors could significantly influence future prices?
Introduction of biosimilars, regulatory changes, formulation innovations, and shifts in prescribing patterns based on safety data.
4. How does safety data impact pricing and market penetration?
Negative safety data can limit prescribing, reduce demand, and pressure prices downward. Conversely, favorable safety profiles support continued market growth.
5. What is the outlook for the TRT market in the next decade?
Steady growth, driven by demographic trends, with potential fluctuations based on regulatory and safety considerations.
References
[1] MarketResearch.com. "Global Testosterone Replacement Therapy Market Size." 2022.
[2] FDA. "Xyosted (testosterone enanthate) prescribing information." 2018.
[3] IQVIA. "U.S. Prescriptions for Testosterone Products." 2022.
[4] Endocrine Society. "Clinical Practice Guidelines on Testosterone Therapy." 2018.
